Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ALL de novo high-risk criteria~* Age 15-55 years (55-60 years patients will be included at the discretion of the medical team that will attend)~* No prior treatment, except Emergency leukapheresis Emergency treatment of hyperleukocytosis with hydroxyurea Urgent cranial irradiation (one dose) for CNS leukostasis Mediastinal irradiation for urgent superior vena cava syndrome~* General condition suitable scale (ECOG 0-2), or\> 2 if due to ALL~* Negative pregnancy test for women of childbearing age~* Written informed consent because, although the protocol does not include the use of investigational drugs, biological samples sent there for them~Exclusion Criteria:~* L3 type ALL or mature phenotype B (sIg +) or cytogenetic abnormalities characteristic of mature B-ALL (t (8; 14), t (2, 8), t (8; 22)). For these patients is available BURKIMAB protocol.~* LAL Ph (BCR-ABL) positive. For these patients have the protocol ALL-Ph-08 (if under 55) or LALOPh (if over 55).~* Lymphoid blast crisis of chronic myeloid leukemia~* Biphenotypic acute leukemia or bilinear according to the criteria of EGIL group~* Undifferentiated acute leukemias~* Patients with a history of coronary artery disease, valvular or hypertensive heart disease, contraindicating the use of anthracyclines~* Patients with chronic phase of activity~* Patients with severe chronic respiratory failure~* Kidney failure due to ALL~* Serious neurological disorder not due to the LAL~* History of pancreatitis~* Pregnancy or breastfeeding~* Mental or psychiatric illness preventing informed consent is given for sending samples or properly follow the study~* General condition affected, not attributable to the ALL

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud (Type: None): Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5

Based on this trial design, predict the completion outcome and termination type (if applicable).